TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Investigators at McGill University publish new data on tuberculosis
December 30th, 2008
"Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity. Shorter and safer regimens are needed," researchers in Montreal, Canada report. "To compare the frequency of adverse events and treatment completion in 2 treatment regimens for latent tuberculosis infection. Multicenter, randomized, open-label trial. Tuberculosis clinics located in university hospitals in Canada, Brazil, and Saudi Arabia. 847 patients without a contraindication for rifampin and requiring treatment for latent tuberculosis infection. Four months of daily rifampin...
Source: TB & Outbreaks Week (2008-12-30)
|
